San Diego-based mostly Viking Therapeutics marked alone as a significant competitor within the weight loss drug marketplace in February soon after revealing promising information from a mid-stage trial of experimental drug VK2735, which instructed it rivaled—and outperformed—Novo and Lilly drugs when specified for a weekly injection As well as